Given the prevalent expression of survivin in PCa bone metastasis [13–15] and the promising pre-clinical results presented here, BKM1644 could be developed as a novel small-molecule therapy to enhance standard chemotherapy and improve clinical outcomes in mCRPC patients. Here, BIRC5 is linked to posterior cortical atrophy.